Passage Bio Inc (PASG) FinancialsPASGPassage Bio Inc

Evaluating the bottom line, Passage Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -169.09%, provide a clear picture of how effectively PASG converts its operational activities into shareholder value.

In the context of the broader market, PASG competes directly with industry leaders such as RGNT and INTS. With a market capitalization of $14.54M, it holds a leading position in the sector. When comparing efficiency, PASG's gross margin of N/A stands against RGNT's N/A and INTS's N/A. Such benchmarking helps identify whether Passage Bio Inc is trading at a premium or discount relative to its financial performance.

Passage Bio has reported consistent losses, with a net income of -$19.34 million in Q3 2024 and a current ratio that has fallen from 5.15 to 1.22 over the past two years, indicating deteriorating financial health.